Attillaps Holdings is a privately-held biotechnology company focused on developing skin microbiome-based therapies for the treatment of inflammation.  Our novel approach places our clinical candidates in a unique position to target a new microbe thought to be at the root of the etiology of numerous inflammatory diseases.

Attillaps leverages its target discovery and characterization expertise to identify new pathways and develop unique, first-in-class therapies by repositioning compounds to treat dermatology, ophthalmology and autoimmune conditions.


Our Founders

Frank A. Spallitta | CEO & Founder

Frank began his career in dermatology 10+ years ago working in the surgical laser industry. He spent the first half of his career with Cynosure, acquired by Hologics in 2017 and the second half with Zeltiq Aesthetics, acquired by Allergan in 2017.  He founded Attillaps with the goal of developing a new approach to treating dermatological conditions with unknown etiologies with a particular interest in the skin microbiome. 

Mr. Spallitta graduated from the University of Iowa with a BBA in Marketing and a Certificate in Entrepreneurial Management from the Tippie College of Business.

Michael E. Wachs, M.D. | CSO & Co-Founder

Michael Wachs is a professor of surgery at the University of Colorado School of Medicine and Surgical Director of Liver/Kidney Transplant at The Children’s Hospital Colorado.  He co-founded Attillaps Holdings in 2013 using his scientific expertise in immunological sciences to help push a paradigm shifting approach to treating inflammatory conditions.

​Dr. Wachs graduated with an AB from Harvard University in Physical Anthropology he attained his MD at the Icahn School of Medicine at Mount Sinai.  He was Chief resident at the University Health Center of Pittsburgh and performed his Transplantation Fellowship at University of California San Francisco Medical Center.

<span>%d</span> bloggers like this: